Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?

@article{Custers2015FearOP,
  title={Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles?},
  author={Jos{\'e} A. E. Custers and Ronald Tielen and Judith B. Prins and Johannes H.W. de Wilt and Marieke F. M. Gielissen and Winette T.A. van der Graaf},
  journal={Acta Oncologica},
  year={2015},
  volume={54},
  pages={1202 - 1208}
}
Abstract Background. Gastrointestinal stromal tumors (GIST) are rare and before 2000, patients had a dismal prognosis with a median survival of less than a year after tumor metastasis. However, the median overall survival has increased to more than five years following the introduction of imatinib and other tyrosine kinase inhibitors (TKI). Little is known about the psychosocial consequences of treatment of GIST, but this is important because patients now are treated and live for longer. This… 
Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors.
TLDR
The prevalence of severe fatigue in GIST patients compared to matched healthy controls, the impact of fatigue on daily life, and associations between fatigue and current TKI use were determined.
Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study
TLDR
A gap was observed between the biomedical perspective on disease that health professionals typically adopt and the individual experiences of patients living with metastatic GIST, which suggests a holistic view of health on the part of their healthcare providers seems crucial.
High Fear of Disease Occurrence Is Associated With Low Quality of Life in Patients With Multiple Endocrine Neoplasia Type 1: Results From the Dutch MEN1 Study Group
TLDR
The majority of patients with MEN1 have FDO for themselves and even more for their relatives, and emphasis should also be placed on FDO and quality of life.
Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden*
TLDR
There is a small, vulnerable group of caregivers with high levels of burden and/or distress, show more health-related problems, both physical and mental, and require adequate support.
Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross- sectional assessment of their distress and burden*
Background: TKIs are a long-term treatment for GIST, and may have an impact on caregivers. Material and Methods: For this cross-sectional study, patients and caregivers were both included when
Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies.
TLDR
This review has shown the need for standardization of Damocles syndrome definitions and the lack of interventional studies that target survivors' psychosocial challenges calls for prospective research to better address this rising problem.
Fear of Cancer Recurrence and Its Impacts on Quality of Life in Family Caregivers of Patients With Head and Neck Cancers
TLDR
The results suggest that FCs caring for Patients with a relatively short posttreatment duration experience higher levels of FCR than those caring for patients with a longer post treatment duration.
Striving towards Normality in Daily Life: A Qualitative Study of Patients Living with Metastatic Gastrointestinal Stromal Tumour in Long-Term Clinical Remission
TLDR
How the daily practical and psychosocial life of patients with chronic cancer, including metastatic GIST, is affected by their disease is focused on to provide health-care workers with clues regarding how to guide and support such patients throughout their emotional journey and to improve their quality of life.
Internet-Delivered Cognitive Behavioral Therapy and Psychoeducation Program for Patients with Gastrointestinal Stromal Tumors.
TLDR
Both intervention programs showed reductions in the dimensions of fatigue and improvements in distress and dimensions of quality of life.
A growing epidemic: cancer treatment consequences.
  • D. Greenfield
  • Medicine
    Current opinion in supportive and palliative care
  • 2017
TLDR
A contemporaneous review examining recent developments in the areas of prevention, early detection, and monitoring of these unwanted side-effects of cancer treatment has been provided.
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Experiences and perspectives on the GIST patient journey
TLDR
Patients with primary or unresectable/metastatic GIST shared similar journeys, especially regarding uncertainty, although differences in the scope and timing of phases were observed.
Adjuvant treatment of GIST: patient selection and treatment strategies
  • H. Joensuu
  • Medicine
    Nature Reviews Clinical Oncology
  • 2012
TLDR
A strategy that involves GIST risk assessment following surgery using a validated scheme, administration of adjuvant imatinib for 3 years, patient monitoring during and after completion of Imatinib to detect recurrence early, and reinstitution ofImatinib if GIST recurs is a reasonable choice for care of patients with high-risk GIST.
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
TLDR
Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo and overall survival of GIST patients with a high risk of Gist recurrence.
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase
Gastrointestinal stromal tumor: psychosocial characteristics and considerations
TLDR
This is the first study to explore the psychosocial impact of GIST, where individuals living with GIST experience chronic pain, post-trauma symptoms and significant anxiety along with an expressed need for interventions to help them manage their anxiety.
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
  • C. Blanke, G. Demetri, +10 authors H. Joensuu
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
TLDR
Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.
Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options
TLDR
Development of small molecules that inhibit the kinase activity of mutant C‐KIT and PDGFR proteins has radically changed treatment and prognosis of patients diagnosed with advanced GIST as this molecularly “targeted” therapy has demonstrated remarkable high‐level of activity in this disease.
Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
www.thelancet.com Vol 368 October 14, 2006 1329 Introduction Gastrointestinal stromal tumours are a form of sarcoma and the most common mesenchymal tumour of the gastrointestinal tract,
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
TLDR
The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.
...
1
2
3
4
...